Individual Adjustment
Neurogene Details New Safety Measures After Young Patient’s Death in Rett Syndrome AAV Gene Therapy Trial
Neurogene; AAV gene therapy; Rett syndrome; NGN-401; ASGCT; safety measures; HLH; clinical trial; MECP2 gene; FDA; dose adjustment
Over 500 BMS jobs axed in latest round of NJ cuts
Bristol Myers Squibb (BMS), Layoffs, New Jersey, Lawrenceville campus, Worker Adjustment and Retraining Notification (WARN), Pharmaceutical industry job cuts, Employment reduction